Asahi Kasei, a Japanese conglomerate, is making a move to buy Swedish biotech company Calliditas Therapeutics for nearly $1.1 billion in a cash deal. The offer of $19.68 per share represents an 83% premium over Calliditas’ closing price on a Swedish exchange. Calliditas has an approved drug called Tarpeyo for treating a kidney disease called IgA nephropathy in the U.S. market. The company’s board has recommended that shareholders accept the offer, as they believe joining a larger platform will bring benefits. This acquisition reflects the growing interest in the biotech and pharma industry for developing new treatments.
Source link
Asahi Kasei to buy Calliditas, picking up kidney disease drug
